The endothelin system as a therapeutic target in cardiovascular disease: Great expectations or bleak house?

British Journal of Pharmacology

Volumn 153, Issue 6, 2008, Pages 1105-1119

  Kirkby, N S ^a   Hadoke, P W F ^a   Bagnall, A J ^a   Webb, D J ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cardiovascular disease; Clinical trials; ECE inhibitors; Endothelin receptor antagonists; Endothelin 1

Indexed keywords

2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; 2 [3 [1 (2 CARBOXY 4 PHENYLBUTYL)CYCLOPENTANECARBOXAMIDO] 2,3,4,5 TETRAHYDRO 2 OXO 1H 1 BENZAZEPIN 1 YL]ACETIC ACID; 5,6,8,13 TETRAHYDRO 1,6,9,14 TETRAHYDROXY 3 (2 HYDROXYPROPYL) 7 METHOXY 8,13 DIOXOBENZO[A]NAPHTHACENE 2 CARBOXYLIC ACID; AMBRISENTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; B 90063; BOSENTAN; CAPTOPRIL; CGS 26393; CGS 31447; CGS 34043; CGS 35066; CGS 35601; CGS 37808; DAGLUTRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME INHIBITOR; LOSARTAN; N ACETYL 3,3 DIPHENYL DEXTRO ALANYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; PD 069185; PD 159790; PHOSPHORAMIDON; RO 687629; SCH 54470; SITAXSENTAN; SM 19712; TMC 66; UNCLASSIFIED DRUG; WS 75624B;

ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; HEART FAILURE; HEART HYPERTROPHY; HEART RIGHT VENTRICLE FAILURE; HUMAN; IN VITRO STUDY; INFLAMMATION; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE; SYNTHESIS; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASOCONSTRICTION;

ANIMALS; ASPARTIC ENDOPEPTIDASES; CARDIOVASCULAR DISEASES; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; ENDOTHELIN-1; ENZYME INHIBITORS; HUMANS; METALLOENDOPEPTIDASES; RECEPTORS, ENDOTHELIN;

EID: 40949132561     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707516     Document Type: Review

References (165)

1. Abassi ZA, Tate JE, Golomb E, Keiser HR (1992). Role of neutral endopeptidase in the metabolism of endothelin. Hypertension 20: 89-95.
2. Ahn D, Ge YQ, Stricklett PK, Gill P, Taylor D, Hughes AK et al. (2004). Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest 114: 504-511.
3. Ahn K, Sisneros AM, Herman SB, Pan SM, Hupe D, Lee C et al. (1998). Novel selective quinazoline inhibitors of endothelin converting enzyme-1. Biochem Biophys Res Commun 243: 184-190.
4. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM et al. (2004). Endothelium-restricted over-expression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 110: 2233-2240.
5. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K et al. (2004). Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin(A) Receptor antagonist Trial in Heart failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364: 347-354.
6. Anggard E, Galton S, Rae G, Thomas R, McLoughlin L, DeNucci G et al. (1989). The fate of radioiodinated endothelin-1 and endothelin-3 in the rat. J Cardiovasc Pharmacol 13: S46-S49.
7. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S (1990). Cloning and expression of a cDNA-encoding an endothelin receptor. Nature 348: 730-732.
8. Aramori I, Nirei H, Shoubo M, Sogabe K, Nakamura K, Kojo H et al. (1993). Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol Pharmacol 43: 127-131.
9. Asai Y, Nonaka N, Suzuki SI, Nishio M, Takahashi K, Shima H et al. (1999). TMC-66, a new endothelin converting enzyme inhibitor produced by Streptomyces sp. A5008. J Antibiot 52: 607-612.
10. Bagnall AJ, Kelland NF, Gulliver-Sloan F, Davenport AP, Gray GA, Yanagisawa M et al. (2006). Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension 48: 286-293.
11. Barnes K, Brown C, Turner AJ (1998). Endothelin-converting enzyme - ultrastructural localization and its recycling from the cell surface. Hypertension 31: 3-9.
12. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S et al. (2004). Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169: 441-447.
13. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J (2002). Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension - open-label pilot study. Chest 121: 1860-1868.
14. Battistini B, Berthiaume N, Kelland NF, Webb DJ, Kohan DE (2006). Profile of past and current clinical trials involving endothelin receptor antagonists: the novel '-sentan' class of drug. Exp Biol Med 231: 653-695.
15. Battistini B, Daull P, Jeng AY (2005). CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme. Cardiovasc Drug Rev 23: 317-330.
16. Bloch KD, Hong CC, Eddy RL, Shows TB, Quertermous T (1991). cDNA cloning and chromosomal assignment of the endothelin-2 gene - vasoactive intestinal contractor peptide is rat endothelin-2. Genomics 10: 236-242.
17. Bonderman D, Nowotny R, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Klepetko A et al. (2005). Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128: 2599-2603.
18. Burrell KM, Molenaar P, Dawson PJ, Kaumann AJ (2000). Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J Pharmacol Exp Ther 292: 449-459.
19. Cardillo C, Kilcoyne CM, Waclawiw M, Cannon III RO, Panza JA (1999). Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 33: 753-758.
20. Cernacek P, Franchi L, Dupuis O, Rouleau JL, Levy M (1998). Radioreceptor assay of an endothelin A receptor antagonist in plasma and urine. Clin Chem 44: 1666-1673.
21. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF et al. (2001). Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358: 1119-1123.
22. Clozel M, Breu V, Gray GA, Kalina B, Loffler BM, Burri K et al. (1994). Pharmacological characterization of bosentan, a new potent orally-active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270: 228-235.
23. Clozel M, Ramuz H, Clozel JP, Breu V, Hess P, Loffler BM et al. (1999). Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 290: 840-846.
24. Cody WL, Doherty AM, He JX, Depue PL, Rapundalo ST, Hingorani GA et al. (1992). Design of a functional hexapeptide antagonist of endothelin. J Med Chem 35: 3301-3303.
25. Cotter G, Kaluski E, Stangl K, Pacher R, Richter C, Milo-Cotter O et al. (2004). The hemodynamic and neuro-hormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail 6: 601-609.
26. Cotter G, Kiowski W, Kaluski E, Kobrin I, Milovanov O, Marmor A et al. (2001). Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure. Eur J Heart Fail 3: 457-461.
27. Cowburn PJ, Cleland JGF, McArthur JD, MacLean MR, McMurray JJV, Dargie HJ (1998). Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure. Lancet 352: 201-202.
28. Davenport AP (2002). International union of pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 54: 219-226.
29. Davenport AP, Maguire JJ (1994). Is endothelin-induced vasoconstriction mediated only by ET(A) receptors in humans. Trends Pharmacol Sci 15: 9-11.
30. DeLombaert S, Blanchard L, Stamford LB, Tan J, Wallace EM, Satoh Y et al. (2000). Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action. J Med Chem 43: 488-504.
31. DeLombaert S, Ghai RD, Jeng AY, Trapani AJ, Webb RL (1994). Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase-24.11 and endothelin-converting enzyme. Biochem Biophys Res Commun 204: 407-412.
32. Dhaun N, Goddard J, Webb DJ (2006). The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 17: 943-955.
33. Dickstein K, De Voogd HJ, Miric MP, Willenbrock R, Mitrovic V, Pacher R et al. (2004). Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol 15: 237-239.
34. Dieterle W, Mann J, Kutz K (2004). Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects. J Clin Pharmacol 44: 59-66.
35. Doherty AM, Cody WL, He JX, Depue PL, Cheng XM, Welch KM et al. (1993). In-vitro and in-vivo studies with a series of hexapeptide endothelin antagonists. J Cardiovasc Pharmacol 22: S98-S102.
36. D'Orleans-Juste P, Labonte J, Bkaily G, Choufani S, Plante M, Honore JC (2002). Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther 95: 221-238.
37. Dupuis J, Jasmin JF, Prie S, Cernacek P (2000). Importance of local production of endothelin-1 and of the ETB receptor in the regulation of pulmonary vascular tone. Pulm Pharmacol Ther 13: 135-140.
38. Emoto N, Yanagisawa M (1995). Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 270: 15262-15268.
39. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B et al. (2001). The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69: 223-231.
40. Fernandez-Patron C, Radomski MW, Davidge ST (1999). Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85: 906-911.
41. Ferro CJ, Spratt JC, Haynes WG, Webb DJ (1998). Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 97: 2323-2330.
42. Firth JD, Ratcliffe PJ (1992). Organ distribution of the 3 rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest 90: 1023-1031.
43. Frelin C, Ladoux A, Marsault R, Vigne P (1991). Functional-properties of high-affinity and low-affinity receptor subtypes for endothelin-3. J Cardiovasc Pharmacol 17: S131-S133.
44. Fukuroda T, Ozaki S, Ihara M, Ishikawa K, Yano M, Nishikibe M (1994). Synergistic inhibition by BQ-123 and BQ-788 of endothelin-1-induced contractions of the rabbit pulmonary artery. Br J Pharmacol 113: 336-338.
45. Furchgott RF, Zawadzki JV (1980). The obligatory role of endothelialcells in the relaxation of arterial smooth-muscle by acetylcholine. Nature 288: 373-376.
46. Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM et al. (2005). Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46: 529-535.
47. Galié N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T et al. (2003). Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 41: 1380-1386.
48. Gariepy CE, Ohuchi T, Williams SC, Richardson JA, Yanagisawa M (2000). Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 105: 925-933.
49. Gavras H, Brunner HR, Turini GA, Kershaw GR, Tifft CP, Cuttelod S et al. (1978). Antihypertensive effect of oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med 298: 991-995.
50. Gavras I, Gavras H (1993). Angiotenisn II - possible adverse effects on arteries, heart, brain and kidney: experimental, clinical and epidemiological evidence, In: Robertson JIS and Nicholls MG (eds). The Renin-Angiotensin System. Gower Medical Publishing: London.
51. Gayraud M (2007). Raynaud's phenomenon. Joint bone. Spine 74: 1-8.
52. Ge YQ, Bagnall A, Stricklett PK, Strait K, Webb DJ, Kotelevtsev Y et al. (2006). Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 291: F1274-F1280.
53. Gillespie MN, Owasoyo JO, McMurtry IF, O'Brien RF (1986). Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial-cells in culture. J Pharmacol Exp Ther 236: 339-343.
54. Goddard J, Eckhart C, Johnston NR, Cumming AD, Rankin AJ, Webb DJ (2004a). Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J Am Soc Nephrol 15: 2601-2610.
55. Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ et al. (2004b). Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure - a comparison of selective and combined endothelin receptor blockade. Circulation 109: 1186-1193.
56. Grandjean T, Rivier JL (1968). Cardio-circulatory effects of beta-adrenergic blockade in organic heart disease. Comparison between propranolol and CIBA 39 089-Ba. Br Heart J 30: 50-59.
57. Gray GA, Webb DJ (1996). The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther 72: 109-148.
58. Gregan B, Jurgensen J, Papsdorf G, Furkert J, Schaefer M, Beyermann M et al. (2004). Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem 279: 27679-27687.
59. Harada H, Kazami J, Watanuki S, Tsuzuki R, Sudoh K, Fujimori A et al. (2001). Ethenesulfonamide and ethanesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists. Bioorg Med Chem 9: 2955-2968.
60. Harrison VJ, Corder R, Anggard EE, Vane JR (1993). Evidence for vesicles that transport endothelin-1 in bovine aortic endothelial cells. J Cardiovasc Pharmacol 22: S57-S60.
61. Haynes WG, Ferro CJ, O'Kane KPJ, Somerville D, Lomax CC, Webb DJ (1996). Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93: 1860-1870.
62. Haynes WG, Webb DJ (1992). Endothelin - a long-acting local constrictor hormone. Br J Hosp Med 47: 340-349.
63. Haynes WG, Webb DJ (1994). Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344: 852-854.
64. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF (1985). Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 248: C550-C556.
65. Hirata Y, Yoshimi H, Takagi Y, Kanno K, Eguchi S, Marumo F (1990). Interaction of endothelin isopeptides with vascular endothelin-1 receptor. Biomed Res - Tokyo 11: 195-198.
66. Hoang MV, Turner AJ (1997). Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin. Biochem J 327: 23-26.
67. Humbert M, Cabane J (2003). Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology 42: 191-193.
68. Ihara M, Ishikawa K, Fukuroda T, Saeki T, Funabashi K, Fukami T et al. (1992). In vitro biological profile of a highly potent novel endothelin (et) antagonist BQ-123 selective for the ET(A) receptor. J Cardiovasc Pharmacol 20: S11-S14.
69. Ikura T, Sawamura T, Shiraki T, Hosokawa H, Kido T, Hoshikawa H et al. (1994). cDNA cloning and expression of bovine endothelin-converting enzyme. Biochem Biophys Res Commun 203: 1417-1422.
70. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K et al. (1989). The human endothelin family - 3 structurally and pharmacologically distinct isopeptides predicted by 3 separate genes. Proc Natl Acad Sci USA 86: 2863-2867.
71. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T et al. (1994). Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA 91: 4892-4896.
72. Ivy DD, Parker TA, Abman SH (2000). Prolonged endothelin B receptor blockade causes pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 279: L758-L765.
73. Ivy DD, Yanagisawa M, Gariepy CE, Gebb SA, Colvin KL, McMurtry IF (2002). Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. Am J Physiol Lung Cell Mol Physiol 282: L703-L712.
74. Jandeleit-Dahm KAM (2006). Dual ACE/NEP inhibitors - more than playing the ACE card. J Human Hypertens 20: 478-481.
75. Janes RW, Peapus DH, Wallace BA (1994). The crystal structure of human endothelin. Nat Struct Biol 1: 311-319.
76. Jeng AY, Mulder P, Kwan AL, Battistini B (2002). Non-peptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications. Can J Physiol Pharmacol 80: 440-449.
77. 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo. Br J Pharmacol 144: 115-122.
78. Kalra PR, Moon JCC, Coats AJS (2002). Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85: 195-197.
79. Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O et al. (2003). RITZ-5: randomized intravenous tezosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema - a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 41: 204-210.
80. Karet FE, Davenport AP (1996). Localization of endothelin peptides in human kidney. Kidney Int 49: 382-387.
81. Karne S, Jayawickreme CK, Lerner MR (1993). Cloning and characterization of an endothelin-3 specific receptor (ET(C) receptor) from Xenopus laevis dermal melanophores. J Biol Chem 268: 19126-19133.
82. Kawai N, Yamamoto T, Yamamoto H, McCarron RM, Spatz M (1997). Functional characterization of endothelin receptors on cultured brain capillary endothelial cells of the rat. Neurochem Int 31: 597-605.
83. Kelland NF, Webb DJ (2006). Clinical trials of endothelin antagonists in heart failure: a question of dose? Exp Biol Med 231: 696-699.
84. Kim NN, Dhir V, Azadzoi KM, Traish AM, Flaherty E, Goldstein I (2002). Pilot study of the endothelin - a receptor selective antagonist BMS-193884 for the treatment of erectile dysfunction. J Androl 23: 76-83.
85. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E et al. (1995). Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346: 732-736.
86. Klipper E, Levy N, Gilboa T, Muller L, Meidan R (2006). Identification of a novel alternatively spliced variant endothelin converting enzyme-1 lacking a transmembrane domain. Exp Biol Med 231: 723-728.
87. Kloog Y, Ambar I, Sokolovsky M, Kochva E, Wollberg Z, Bdolah A (1988). Sarafotoxin, a novel vasoconstrictor peptide-phosphoinositide hydrolysis in rat heart and brain. Science 242: 268-270.
88. Kohan DE (1997). Endothelins in the normal and diseased kidney. Am J Kidney Dis 29: 2-26.
89. Korn JH, Mayes M, Cerinic MM, Rainisio M, Pope J, Hachulla E et al. (2004). Digital ulcers in systemic sclerosis - prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50: 3985-3993.
90. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V (1998). The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 338: 784-790.
91. Kuc RE, Davenport AP (2004). Comparison of endothelin-A and endothelin-B receptor distribution visualized by radioligand binding versus immunocytochemical localization using subtype selective antisera. J Cardiovasc Pharmacol 44: S224-S226.
92. Kukkola PJ, Savage P, Sakane Y, Berry JC, Bilci NA, Ghai RD et al. (1995). Differential structure-activity relationships of phosphoramidon analogs for inhibition of 3 metalloproteases - endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme. J Cardiovasc Pharmacol 26: S65-S68.
93. Kumar C, Mwangi V, Nuthulaganti P, Wu HL, Pullen M, Brun K et al. (1994). Cloning and characterization of a novel endothelin receptor from Xenopus heart. J Biol Chem 269: 13414-13420.
94. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R et al. (1994). Elevated blood-pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 368: 703-710.
95. Lahav R (2005). Endothelin receptor B is required for the expansion of melanocyte precursors and malignant melanoma. Int J Dev Biol 49: 173-180.
96. Masaki T (2004). Historical review: endothelin. Trends Pharmacol Sci 25: 219-224.
97. McKittrick BA, Stamford AW, Weng XY, Ma K, Chackalamannil S, Czarniecki M et al. (1996). Design and synthesis of phosphinic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11. Bioorg Med Chem Lett 6: 1629-1634.
98. Meidan R, Klipper E, Gilboa T, Muller L, Levy N (2005). Endothelin-converting enzyme-1, abundance of isoforms a-d and identification of a novel alternatively spliced variant lacking a transmembrane domain. J Biol Chem 280: 40867-40874.
99. Meyer M, Lehnart S, Pieske B, Schlottauer K, Munk S, Holubarsch C et al. (1996). Influence of endothelin 1 on human atrial myocardium - myocardial function and subcellular pathways. Basic Res Cardiol 91: 86-93.
100. Mickley EJ, Gray GA, Webb DJ (1997). Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries. Br J Pharmacol 120: 1376-1382.
101. Mihara SI, Nakajima S, Matumura S, Kohnoike T, Fujimoto M (1994). Pharmacological characterization of a potent nonpeptide endothelin receptor antagonist, 97-139. J Pharmacol Exp Ther 268: 1122-1128.
102. Mizuguchi T, Nishiyama M, Moroi K, Tanaka H, Saito T, Masuda Y et al. (1997). Analysis of two pharmacologically predicted endothelin B receptor subtypes by using the endothelin B receptor gene knockout mouse. Br J Pharmacol 120: 1427-1430.
103. Molenaar P, O'Reilly G, Sharkey A, Kuc RE, Harding DP, Plumpton C et al. (1993). Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res 72: 526-538.
104. Morita S, Kitamura K, Yamamoto Y, Eto T, Osada Y, Sumiyoshi A et al. (1991). Immunoreactive endothelin in human kidney. Ann Clin Biochem 28: 267-271.
105. Morris CD, Rose A, Curwen J, Hughes AM, Wilson DJ, Webb DJ (2005). Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 92: 2148-2152.
106. Motte S, McEntee K, Naeije R (2006). Endothelin receptor antagonists. Pharmacol Ther 110: 386-414.
107. Muller DN, Mullally A, Dechend R, Park JK, Fiebeler A, Pilz B et al. (2002). Endothelin-converting enzyme inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension 40: 840-846.
108. Murugesan N, Gu ZX, Spergel S, Young M, Chen P, Mathur A et al. (2003). Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2′-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl) [1,1′-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ETA selective antagonist. J Med Chem 46: 125-137.
109. Murugesan N, Gu ZX, Stein PD, Spergel S, Mathur A, Leith L et al. (2000). Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4′-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ETA antagonists. J Med Chem 43: 3111-3117.
110. Mylona P, Cleland JGF (1999). Update of REACH-1 and MERIT-HF clinical trials in heart failure. Eur J Heart Fail 1: 197-200.
111. Nguyen QT, Cernacek P, Calderoni A, Stewart DJ, Picard P, Sirois P et al. (1998). Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation 98: 2323-2330.
112. Nunez DJR, Brown MJ, Davenport AP, Neylon CB, Schofield JP, Wyse RK (1990). Endothelin-1 messenger-RNA is widely expressed in porcine and human tissues. J Clin Invest 85: 1537-1541.
113. O'Connor CM, Gattis WA, Adams KF, Hasselblad V, Chandler B, Frey A et al. (2003). Tezosentan in patients' with acute heart failure and acute coronary syndromes - results of the Randomized Intravenous Tezosentan study (RITZ-4). J Am Coll Cardiol 41: 1452-1457.
114. O'Connor CM, Gattis WA, Adams KF, Shah MR, Kobrin I, Frey A et al. (2002). Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4). Am Heart J 144: 583-588.
115. Ohlstein EH, Nambi P, Lago A, Hay DWP, Beck G, Fong KL et al. (1996). Nonpeptide endothelin receptor antagonists. 6. Pharmacological characterization of SE 217242, a potent and highly bioavailable endothelin receptor antagonist. J Pharmacol Exp Ther 276: 609-615.
116. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB et al. (1996). Pharmacological characterization of A-127722: an orally active and highly potent ET(A)-selective receptor antagonist. J Pharmacol Exp Ther 276: 473-481.
117. Opgenorth TJ, Wuwong JR, Shiosaki K (1992). Endothelin-converting enzymes. FASEB J 6: 2653-2659.
118. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 334: 1349-1355.
119. Pernow J, Bohm F, Johansson BL, Hedin U, Ryden L (2000). Enhanced vasoconstrictor response to endothelin-B-receptor stimulation in patients with atherosclerosis. J Cardiovasc Pharmacol 36: S418-S420.
120. Properzi G, Terenghi G, Gu XH, Poccia G, Pasqua R, Francavilla S et al. (1995). Early increase precedes a depletion of endothelin-1 but not of von Willebrand factor in cutaneous microvessels of diabetic patients, a quantitative immunohistochemical study. J Pathol 175: 243-252.
121. Quaschning T, Rebhan B, Wunderlich C, Wanner C, Richter CM, Pfab T et al. (2005). Endothelin B receptor-deficient mice develop endothelial dysfunction independently of salt loading. J Hypertens 23: 979-985.
122. Ramos-Casals M, Brito-Zeron P, Nardi N, Claver G, Risco G, Parraga FD et al. (2004). Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology 43: 1454-1456.
123. Reinhart GA, Preusser LC, Burke SE, Wessale JL, Wegner CD, Opgenorth TJ et al. (2002). Hypertension induced by blockade of ETB receptors in conscious nonhuman primates: role of ETA receptors. Am J Physiol Heart Circ Physiol 283: H1555-H1561.
124. Resink TJ, Hahn AWA, Scott-Burden T, Powell J, Weber E, Buhler FR (1990). Inducible endothelin messenger RNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun 168: 1303-1310.
125. Riechers H, Albrecht HP, Amberg W, Baumann E, Bernard H, Bohm HJ et al. (1996). Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J Med Chem 39: 2123-2128.
126. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P et al. (1997). Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 283: 1110-1118.
127. Rubanyi GM, Polokoff MA (1994). Endothelins - molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46: 325-415.
128. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al. (2002). Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896-903.
129. Rubinstein I, Gurbanov K, Hoffman A, Better OS, Winaver J (1995). Differential effect of endothelin-1 on renal regional blood-flow - role of nitric-oxide. J Cardiovasc Pharmacol 26: S208-S210.
130. Russell FD, Davenport AP (1999). Secretory pathways in endothelin synthesis. Br J Pharmacol 126: 391-398.
131. Sakamoto A, Yanagisawa M, Sakurai T, Takuwa Y, Yanagisawa H, Masaki T (1991). Cloning and functional expression of human cDNA for the ETB endothelin receptor. Biochem Biophys Res Commun 178: 656-663.
132. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K et al. (1990). Cloning of a cDNA-encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348: 732-735.
133. Schalcher C, Cotter G, Reisin L, Bertel O, Kobrin I, Guyene TT et al. (2001). The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J 142: 340-349.
134. Schiffrin EL (1995). Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 25: 1135-1143.
135. Schmidt M, Kroger B, Jacob E, Seulberger H, Subkowski T, Otter R et al. (1994). Molecular characterization of human and bovine endothelin-converting enzyme (ECE-1). FEBS Lett 356: 238-243.
136. Shetty SS, Savage P, DelGrande D, De Lombaert S, Jeng AY (1998). Characterization of CGS 31447, a potent and non-peptidic endothelin-converting enzyme inhibitor. J Cardiovasc Pharmacol 31: S68-S70.
137. Shi SJ, Rakugi H, Higashimori K, Jiang BB, Higaki J, Mikami H et al. (1994). Augmentation by converting-enzyme inhibition of accelerated endothelin release from rat mesenteric-arteries following nephrectomy. Biochem Biophys Res Commun 202: 246-251.
138. Snyder MJ, Jacobs MR, Grau RG, Wilkes DS, Knox KS (2005). Resolution of severe digital ulceration during a course of bosentan therapy. Ann Intern Med 142: 802-803.
139. Spatz M, Kawai N, Merkel N, Bembry J, McCarron RM (1997). Functional properties of cultured endothelial cells derived from large microvessels of human brain. Am J Physiol 272: C231-C239.
140. Spieker LE, Mitrovic V, Noll G, Pacher R, Schulze MR, Muntwyler J et al. (2000). Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patients with congestive heart failure. J Am Coll Cardiol 35: 1745-1752.
141. Stewart DJ, Levy RD, Cernacek P, Langleben D (1991). Increased plasma endothelin-1 in pulmonary-hypertension - marker or mediator of disease. Ann Intern Med 114: 464-469.
142. Strachan FE, Spratt JC, Wilkinson IB, Johnston NR, Gray GA, Webb DJ (1999). Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 33: 581-585.
143. Tabrizchi R (2003). SLV-306. Solvay. Curr Opin Investig Drugs 4: 329-332.
144. Takahashi H, Soma S, Muramatsu M, Oka M, Ienaga H, Fukuchi Y (2001). Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery. Eur Respir J 18: 5-14.
145. Takaishi S, Tuchiya N, Sato A, Negishi T, Takamatsu Y, Matsushita Y et al. (1998). B-90063, a novel endothelin converting enzyme inhibitor isolated from a new marine bacterium, Blastobacter sp. SANK 71894. J Antibiot 51: 805-815.
146. Torre-Amione G, Durand JB, Nagueh S, Vooletich MT, Kobrin I, Pratt C (2001a). A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure. Chest 120: 460-466.
147. Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G et al. (2003). Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 42: 140-147.
148. Torre-Amione G, Young JB, Durand JB, Bozkurt B, Mann DL, Kobrin I et al. (2001b). Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class iii-iv congestive heart failure. Circulation 103: 973-980.
149. Trapani AJ, Beil ME, Bruseo CW, De Lombaert S, Jeng AY (2000). Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious rats. J Cardiovasc Pharmacol 36: S40-S43.
150. Trapani AJ, Beil ME, Bruseo CW, Savage P, Firooznia F, Jeng AY (2004). CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme. J Cardiovasc Pharmacol 44: S211-S215.
151. Tschudi MR, Luscher TF (1994). Characterization of contractile endothelin and angiotensin receptors in human resistance arteries - evidence for 2 endothelin and one angiotensin receptor. Biochem Biophys Res Commun 204: 685-690.
152. Tsurumi Y, Fujie K, Nishikawa M, Kiyoto S, Okuhara M (1995a). Biological and pharmacological properties of highly selective new endothelin-converting enzyme-inhibitor WS79089B isolated from Streptosporangium roseum no-79089. J Antibiot 48: 169-174.
153. Tsurumi Y, Ueda H, Hayashi K, Takase S, Nishikawa M, Kiyoto S et al. (1995b). WS75624-A and WS75624-B, new endothelin-converting enzyme-inhibitors isolated from Saccharothrix sp. no-75624. 1. Taxonomy, fermentation, isolation, physicochemical properties and biological-activities. J Antibiot 48: 1066-1072.
154. Umekawa K, Hasegawa H, Tsutsumi Y, Sato K, Matsumura Y, Ohashi N (2000). Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme. Jpn J Pharmacol 84: 7-15.
155. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F et al. (2005). Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 103: 9-17.
156. Valdenaire O, Lepailleur-Enouf D, Egidy G, Thouard A, Barret A, Vranckx R et al. (1999). A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter - molecular cloning and characterization. Eur J Biochem 264: 341-349.
157. von Geldern TW, Tasker AS, Sorensen BK, Winn M, Szczepankiewicz BG, Dixon DB et al. (1999). Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ETB selectivity. J Med Chem 42: 3668-3678.
158. Watanabe T, Awane Y, Ikeda S, Fujiwara S, Kubo K, Kikuchi T et al. (1995). Pharmacology of a nonselective ET(A) and ET(B) receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br J Pharmacol 114: 949-954.
159. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, vanMarle SP, Peeters PAM et al. (1996). Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60: 124-137.
160. Whitebread S, Mele M, Kamber B, Degasparo M (1989). Preliminary biochemical characterization of two angiotensin-II receptor subtypes. Biochem Biophys Res Commun 163: 284-291.
161. Wu CD, Chan MF, Stavros F, Raju B, Okun I, Mong S et al. (1997). Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 40: 1690-1697.
162. Wu CD, Decker ER, Blok N, Bui H, You TJ, Wang JM et al. (2004). Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6- dimethylphenyl)-3-(3,4-dimethylisoxazol-5-sulfamoyl) thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist. J Med Chem 47: 1969-1986.
163. Wypij DM, Nichols JS, Novak PJ, Stacy DL, Berman J, Wiseman JS (1992). Role of mast-cell chymase in the extracellular processing of big-endothelin-1 to endothelin-1 in the perfused rat lung. Biochem Pharmacol 43: 845-853.
164. Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC, Takeda S et al. (2000). Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest 105: 1373-1382.
165. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415.